Background: The combinations of methotrexate, vinblastine, Adriamycin, cisplatin (Pharmanell, Athens, Greece) (MVAC) or gemcitabine, cisplatin (GC) represent the standard treatment of advanced urothelial cancer (UC). Dosedense (DD)-MVAC has achieved longer progression-free survival (PFS) than the conventional MVAC. However, the role of GC intensification has not been studied. We conducted a randomized, phase III study comparing a DD-GC regimen with DD-MVAC in advanced UC. Results: The median overall survival (OS) and PFS were 19 and 8.5 months for DD-MVAC and 18 and 7.8 months for DD-GC (P = 0.98 and 0.36, respectively). Neutropenic infections were less frequent for DD-GC than for DD-MVAC (0% versus 8%). More patients on DD-GC received at least six cycles of treatment (85% versus 63%, P = 0.011) and the discontinuation rate was lower for DD-GC (3% versus 13%).
introduction
Urothelial cancer (UC) is a common malignancy originating from the transitional epithelium lining the renal pelvis, ureters, urinary bladder and the urethra. The incidence in Europe is 10-29 cases and the mortality is five to eight cases per 100 000 persons per year [1] . Most cases present as superficial cancers, requiring only local treatment. Nevertheless, 25% of UCs are invasive, while 5% present with metastatic disease. In addition, about half of the patients undergoing surgery for invasive disease will relapse. The treatment of choice for inoperable, metastatic or recurrent disease is systemic chemotherapy. The chemosensitivity of UC has been established, since 1985, with the combination of methotrexate, vinblastine, doxorubicin (Pharmanell, Athens, Greece) (Adriamycin) and cisplatin (MVAC) [2] , showing response rates (RRs) of >50%, 3-year survival rate of 20%-25% and median survival past 1 year consistently reported [3] [4] [5] . Still, cure remains rare. The combination of gemcitabine and cisplatin (GC) has been established as an alternative to MVAC, after the results of a randomized study showing comparable efficacy with a milder toxicity profile [6] . Such improved tolerability has also been shown for classic MVAC, when granocyte-colony stimulating factors (G-CSF) were routinely used [7] . Nevertheless, both the regimes require weekly visits, which can be bothersome for patients.
A potential improvement over the existing standards has been suggested by the use of dose-dense (DD) chemotherapy. In a randomized, phase III study, DD-MVAC [doubling the dose intensity (DI) of cisplatin and doxorubicin] was compared with the classic 28-day MVAC [8] . RRs and progression-free survival (PFS) were significantly improved. Importantly, tolerability was also improved because of the routine use of G-CSF and the biweekly instead of weekly administration. An updated analysis with a median follow-up of 7 years also showed a relative reduction in the risk of death of borderline statistical significance by the DD regimen [9] . Based on these results, DD-MVAC represents an option as first-line treatment for advanced UC. The potential benefit from increasing the dose density of the other standard, GC has not been investigated in this disease.
Preclinical as well as clinical data have suggested that the efficacy of gemcitabine might be improved by dose intensification. Preclinical studies using human tumor colonyforming units from pancreatic cancer patients or tumor cell lines [10] have suggested a dose-dependent relationship. These observations have been supported by clinical trials in patients with non-small-cell lung cancer (NSCLC) [11] and pancreatic cancer [12] showing higher than expected RRs. Furthermore, Sternberg et al. have shown that biweekly paclitaxel (Taxol) and gemcitabine at 2.5-3 g/m 2 achieved a 60% RR in patients with advanced UC who had previously received MVAC, albeit some as perioperative treatment [13] . Apart from paclitaxel, high-dose gemcitabine can be combined with other agents, including cisplatin: in a recent, phase II study, in NSCLC, gemcitabine at 2.5 g/m 2 was safely combined with cisplatin at 50 mg/m 2 [14] , while in a randomized, phase II study in pancreatic cancer, gemcitabine at 2.2 g/m 2 was safely combined with capecitabine [15] .
Based on the above data, we hypothesized that the use of DD-GC might improve the outcome in patients with advanced UC. In order to investigate this hypothesis, we launched an intergroup, randomized, phase III trial comparing a DD-GC combination with DD-MVAC, which had become the treatment of choice in our group after the publication of the results of the EORTC study [9] .
patients and methods

selection and randomization
Patients with histologically confirmed inoperable (cT4b, N2, N3), metastatic or recurrent (after surgery and/or radiotherapy) transitional cell carcinoma of the urothelial tract (renal pelvis, ureter, bladder or urethra) were included in the study. Patients should have adequate bone marrow and liver function [absolute neutrophil count (ANC) >1500/μl, platelets >100 000/μl, bilirubin and aminotransferases<2 upper limit of normal], creatinine clearance (Cockroft formula) >50 ml/min, Eastern Cooperative Oncology Group (ECOG) PS 0 or 1 and the absence of moderate or severe heart failure. No previous chemotherapy for advanced disease was allowed. Prior adjuvant or neoadjuvant treatment was allowed, provided that it had been completed at least 12 months before study entry and it did not contain anthracyclines. Patients with history of cardiac disease should be evaluated with echocardiography to ensure adequate left ventricular function. The study protocol received approval from the appropriate Institutional and National Review Boards. Patients gave their written informed consent before enrollment to the study.
Randomization was carried out centrally after stratification for disease site [locoregional disease (unresectable tumor and/or lymph node metastases at any site including pelvis, retroperitoneum, mediastinum, and neck) versus distant metastases (any other site)] and participating center. both given every 2 weeks with G-CSF support (days 5-9). Cisplatin was administered with adequate pre-and post-hydration, while gemcitabine was diluted in 250 ml of normal saline and was administered within 30 min. The G-CSF was administered on days 5-9. The dose of gemcitabine was based on the only data available at the time of the design of the study regarding the combination of high-dose gemcitabine with cisplatin [14] . This regimen resulted in a twofold increase in the DI of cisplatin and 1.66-fold increase of gemcitabine, compared with the standard GC [6] . The treatment was administered to a minimum of six cycles, unless progression, intolerable toxicity or withdrawal of consent occurred earlier. Treatment beyond 6 cycles (up to a maximum of 12 cycles) continued at the discretion of the treating physician. Tumor assessment was carried out every four cycles of treatment unless there was clinical indication of progression. RECIST criteria [16] were used for classifying response. Toxicity was evaluated at each chemotherapy visit according to National Cancer Institute Common Toxicity Criteria, v. 3. Relative dose-intensity was defined as the percentage of the expected dose administered to the patient (expressed in mg/m 2 /week).
The details of baseline evaluation, dose modifications and follow-up after therapy are outlined in the supplementary material, available at Annals of Oncology online.
statistical design
The primary objective of the study was the comparison of overall survival (OS) in the two treatment arms. The secondary end points were the comparison of objective response rates (ORR) and PFS.
For a two-sided log rank test at the 5% level of significance and power of 80%, the number of patients required to detect a +15% difference in the survival rate, to a baseline rate of 50% at the 15-month time point, was 200 (152 events). The study accrual rate was estimated at 50 patients per year. Taking into consideration a 3% withdrawal 206 patients needed to enter the study. The maximum study duration was estimated to be 5.6 years (EAST 5.4, Cytel Inc). At the end of the estimated accrual period, only 130 patients had been enrolled. At the same time, a substantial increase in the funding of the study became necessary after the implementation of the European Economic Community directive in Greece regarding the conduct of randomized studies. The combination of slow accrual and lack of adequate funding led to the discontinuation of the study and the number of events was followed yearly to assess the possibility of acquiring the required events with longer follow-up. In September 2010, it became original articles Annals of Oncology apparent that the events would be fewer than anticipated and no realistic chance to meet the initial hypothesis with longer follow-up existed. Therefore, the database was locked in October 2010 and analysis was carried out with a total of 89 events.
Statistical methods are described in supplementary material, available at Annals of Oncology online. results patients One hundred and thirty patients from 12 Greek centers were randomly assigned to DD-MVAC (n = 66) and DD-GC (n = 64) (enrollment period: 11 November 2003-23 January 2008). Three patients were excluded from the analyses because of non-transitional histology and one because of PS 2. The CONSORT diagram is shown in Figure 1 . The baseline characteristics of the eligible patients are shown in Table 1 . Forty-six patients (37%) in the DD-MVAC group and 28 (44%) in the DD-GC underwent a radical surgery for their primary tumor. There were significantly more patients with greater than three metastatic sites in the DD-MVAC group (22.2% versus 6.3%, P = 0.028). There were numerically more patients with PS 0 and visceral metastases in the DD-MVAC group (66.7% versus 49.2% and 42.9% versu 30.2%), but these differences were not significant (P = 0.064 and P = 0.19, respectively). Patients were well balanced according to the modified Memorial Sloan Kettering Cancer Center (MSKCC) risk stratification [17] .
tumor response, PFS and OS
Efficacy data are shown in Table 2 . Ninety-four patients were assessable for response. No differences in ORR between the treatment groups were observed.
At the time of analysis, 99 patients had progressed and 89 patients had died (87 disease-related, 2 treatment-related). The median follow-up for surviving patients was 52.1 months (0.1-82.5). PFS and OS were similar between the two arms (median PFS (Figure 2) . Although, as already mentioned, the study closed prematurely, it is worth noting that at the time of analysis, the conditional power under the alternative (HR = 0.62, ln(HR) = 0.476) was estimated to be <7%. A conditional power assessment at the timepoint the trial stopped would have resulted in a decision of not continuing the trial due to futility.
Univariate analysis showed that the performance status of 0 and good MSKCC risk category were associated with improved OS and PFS, while visceral metastases and greater than three metastatic sites were associated only with inferior PFS (supplementary Table S1 , available at Annals of Oncology online). Exploratory analyses of the interactions of the treatment group and baseline characteristics showed a significant interaction between the treatment group and the PS for OS (Wald's P = 0.034) but not for PFS (Wald's P = 0.24). Figure S1 , available at Annals of Oncology online). In the PS 0 subgroup, no significant difference between the two arms was observed (HR = 1.15, 95% CI 0.64-2.05, Wald's P = 0.64).
Since MSKCC grouping consists of PS and visceral metastases, we ran two multivariate models, one with PS and visceral metastases and one with MSKCC groups alone (Table 3) . PS and MSKCC grouping were significant factors both for OS and PFS, while visceral metastases were also significant for PFS. The interaction of PS with the group was also found to be significant for OS (P = 0.034).
treatment details and toxicity analysis
All patients who received at least one cycle of chemotherapy were assessable for treatment and toxicity analysis. Five patients did not receive protocol therapy, while treatment information was not available in one case. Therefore, these analyses included 120 patients (61 in the DD-MVAC and 59 in the DD-GC arm).
A total of 322 cycles of DD-MVAC and 386 of DD-GC were administered. The median number of cycles in both the arms was 6. Thirty-six patients in the MVAC arm and 39 patients in the GC arm received full doses of the protocol treatment. Significantly more patients treated with DD-GC received at least six cycles of chemotherapy compared with the DD-MVAC patients in the randomized study (85% versus 63%, P = 0.011). The actual and relative DIs for each treatment group are shown in supplementary Table S2 , available at Annals of Oncology online.
The most frequent toxic effects for both the regimes were anemia, thrombocytopenia and fatigue (92% versus 89%, 51% versus 55% and 55% versus 43% for DD-MVAC and DD-GC, respectively). Grade 3-5 toxicities were reported in 30 cases for DD-MVAC (50%) and 26 cases (44%) for DD-GC. All grade >3 toxicities occurring in at least 2% of patients are shown in Table 4 . There were two toxic deaths, both in the DD-MVAC arm due to sepsis (non-neutropenic). More patients discontinued treatment due to toxicity in the DD-MVAC group: 8 (13%) (fatigue, 2; repeated myelotoxicity, 2; neurotoxicity, 1; renal: 1), while only two patients (3%) stopped DD-GC due to auditory and renal toxicity. discussion This is the first study addressing the role of dose intensification of gemcitabine in UC. Intensification of MVAC has shown promising results and is considered by some European Institutions (including our Cooperative Group) as one of the standards in this disease. We, therefore, directly compared DD-MVAC with a DD schedule of the other accepted standard GC. This multicenter phase III study showed a similar efficacy original articles Annals of Oncology between DD-GC and DD-MVAC. The statistical power of the study was limited by the incomplete accrual. The initial design required 152 events to detect a significant increase in the median OS from 15 to 24 months, a similar design to that of the EORTC DD-MVAC study. At the estimated time of completion of accrual, only 65% of the required number of patients had been enrolled, a problem also encountered in other recent randomized studies in bladder cancer [18, 19] . This, in combination with unforeseen administrative issues, led to the premature closure of the study. The rate of events 2 years after the termination of the study was lower than anticipated, precluding a realistic chance of meeting our initial hypothesis. The analysis was carried out with 89 events. A conditional power assessment at the timepoint the trial stopped would have resulted in a decision of not continuing the trial due to futility. A separate analysis including 62 additional patients treated with DD-MVAC produced identical results to this study [20] . We, therefore, believe that useful information has been generated from our study. DD-GC was better tolerated than DD-MVAC: no case of neutropenic fever was reported for DD-GC, as opposed to 5% for DD-MVAC; there were no toxic deaths compared with 2; the treatment was discontinued due to toxicity in only two patients as opposed to eight. Moreover, significantly more patients received at least six cycles. Since this was not due to higher efficacy of DD-GC, we can assume that it was due to better tolerance. The DI of gemcitabine achieved in our study is among the highest ever reported, especially for combination therapy and is higher than that reported for 4-weekly GC, thus achieving the goal of dose intensification. Data from this as well as studies in other tumors suggest that DD-GC is less toxic than the classic 4-weekly GC regimen. The most striking difference is the lower grade 3-4 neutropenia [71% [6] versus 15% (our study)] and thrombocytopenia [57% [6] versus 19% (our study)] rate. Some degree of underreporting cannot be excluded, since weekly blood counts were not required, as it would happen with 4-weekly GC. Nevertheless, these differences are too high to be attributed solely to underreporting. The reduction of myelotoxicity is more likely due to the biweekly administration, rather than the use of G-CSF, since similar results have been reported for the combination of biweekly high-dose gemcitabine with cisplatin [21] or capecitabine [15] without the use of the G-CSF. Furthermore, the reduction in thrombocytopenia cannot be attributed to the use of G-CSF.
The median survival of 18 months and the 3-year survival rate of 26.7% for DD-GC compare favorably with those reported for DD-MVAC, classic MVAC, GC and the PGC triplet, ranging from 12.7 to 15.8 in recent randomized studies [7, 8, 22, 23] . Nevertheless, caution should be exercised in cross study comparisons. Bajorin et al. has shown that impressive differences in survival can be observed by altering the proportion of patients with no or two risk factors [22] . Therefore, superiority of DD-GC over these regimes cannot be claimed by our results. Although the concept of DI was introduced in UC more than a decade ago, data remain too limited for a firm conclusion regarding the role of this approach. The only previous randomized study showed no OS survival benefit by intensifying the dose of cisplatin and doxorubicin [8] . We also did not show any benefit by gemcitabine intensification, but limited statistical power precludes a definite conclusion. Nevertheless, both the studies reported findings, which deserve consideration. In the EORTC study, intensification produced superior RRs and PFS, while our results suggest that there may be groups of patients, who might benefit from this approach. Patients with PS 1 treated with DD-GC had almost half risk of death compared with those treated with DD-MVAC. This interaction was found to be independent in multivariate analysis. The reason for this finding is unclear. Certain molecular characteristics, such as RRM1 mutations, suggest increased sensitivity to gemcitabine [25] . Nevertheless, such mutations have not been associated with PS. The possibility that a DD GC regimen has increased efficacy in the group of symptomatic patients has important clinical implications for the quality of life (QoL) of these patients. Unfortunately, our study did not include QoL assessment. It should be stressed that this was an unplanned analysis, subjective to biases and, therefore, this finding can only be considered as 'hypothesis generating'. Finally, the mild toxicity profile of DD-GC, similarly to the results of the only other study using biweekly gemcitabine at 2500 mg/m 2 combined with 50 mg/m 2 of cisplatin in NSCLC patients [14] , indicates that higher gemcitabine doses could be safely used. Biweekly gemcitabine at doses of up to 3000 mg/m 2 has been used in combination with other agents, such as capecitabine, paclitaxel and vinorelbine [15, 21, 26] . Whether further intensification of gemcitabine in combination with cisplatin would be safe and beneficial in UC can only be concluded by properly designed studies.
In conclusion, further research is required to define the role of dose intensification in UC. Due to the limited statistical power of this study, firm conclusions on the superiority of DD-GC over DD-MVAC in advanced UC cannot be made. Taking into consideration the promising efficacy results, the favorable toxicity profile and the ease of administration, we believe that DD-GC could be considered as a reasonable therapeutic option for further study in this patient population.
